Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA® (Pembrolizumab) in Selected Advanced Solid Tumors
Go back to Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA® (Pembrolizumab) in Selected Advanced Solid Tumors| Goss & De Leeuw Mach Co (NASDAQ: GOSS) | Delayed: 0.17 +0.01 (6.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.16 | 52 Week High | $0.00 | |||
| Open | $0.16 | 52 Week Low | $0.00 | |||
| Day High | $0.18 | P/E | N/A | |||
| Day Low | $0.16 | EPS | $0.00 | |||
| Volume | 13,383,427 | |||||
